GlassScriptPhysician profile
Jose Crossier
NPI 1396209649
$6,890.50
in general payments reported to CMS, 2019-2025
30 companies · $1,897 in 2025
The $1,897 reported for 2025 was more than what 88% of Psychiatric/Mental Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $244).
See the full distribution for Psychiatric/Mental Health (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $348 · 2022: $1,465 · 2023: $1,742 · 2024: $1,439 · 2025: $1,897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,877 · Education: $201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,876.96 |
| Education | $200.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $936.20 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $909.56 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $804.66 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $752.89 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Ironshore Pharmaceuticals INC. | $430.20 | 2022-2024 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $410.43 | 2022-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Tempus Ai, INC | $350.24 | 2024 | |
| Alkermes, INC. | $340.72 | 2022-2025 | Aristada, Lybalvi |
| Almatica Pharma LLC | $326.33 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Axsome Therapeutics, INC. | $231.10 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $200.87 | 2022-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $164.82 | 2022 | |
| Corium, LLC | $136.81 | 2022-2023 | Azstarys |
| Neurocrine Biosciences, INC. | $124.58 | 2022-2025 | Ingrezza |
| Regeneron Healthcare Solutions, INC. | $95.12 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $94.98 | 2023-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $82.55 | 2021-2023 | Belsomra |
| Astrazeneca Pharmaceuticals LP | $74.54 | 2021-2022 | |
| Kaleo, INC. | $64.75 | 2021 | |
| Collegium Pharmaceutical, INC. | $60.65 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $53.88 | 2022-2023 | Quviviq |
| Genzyme Corporation | $46.00 | 2021-2022 | |
| Eyevance Pharmaceuticals LLC | $40.15 | 2021 | |
| Novartis Pharmaceuticals Corporation | $37.79 | 2021-2022 | |
| Glaxosmithkline, LLC. | $28.90 | 2021 | |
| Lilly USA, LLC | $26.03 | 2025 | Kisunla |
| Neos Therapeutics, LP | $16.50 | 2023 | Adzenys Xr-Odt |
| Optinose US, INC. | $16.46 | 2021 | |
| Supernus Pharmaceuticals, INC. | $16.43 | 2023 | Qelbree |
| Bausch Health US, LLC | $16.36 | 2023 | Aplenzin, Wellbutrin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Crossier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.